Evidence map›Paper›PMID 31462766›Full record

Trial reportMolecular psychiatry2020

Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals.

Tsafrir Greenberg, Jay C Fournier, Richelle Stiffler, Henry W Chase, Jorge R Almeida, Haris Aslam, Thilo Deckersbach, Crystal Cooper, Marisa S Toups, Tom Carmody and 11 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Neuroimaging for precision medicine in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  14. Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Tsafrir Greenberg *Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. greenbergt@upmc.edu.
Jay C Fournier *Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Richelle StifflerDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Henry W ChaseDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Jorge R AlmeidaDepartment of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
Haris AslamDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Thilo DeckersbachDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Crystal CooperDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Marisa S ToupsDepartment of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
Tom CarmodyDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Benji KurianDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Scott PeltierFunctional MRI Laboratory, University of Michigan, Ann Arbor, MI, USA.
Phillip AdamsDepartment of Psychiatry, Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute, New York, NY, USA.
Melvin G McInnisDepartment of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-0375-6247
Maria A OquendoDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Maurizio FavaDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Ramin ParseyDepartments of Psychiatry and Behavioral Science & Radiology, Stony Brook University, Stony Brook, NY, USA.
Patrick J McGrathDepartment of Psychiatry, Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute, New York, NY, USA.
Myrna WeissmanDepartment of Psychiatry, Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute, New York, NY, USA.
Madhukar TrivediDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-2983-1110
Mary L PhillipsDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · USThe University of Texas Southwestern Medical Center · USNew York State Psychiatric InstituteMassachusetts General Hospital · USThe University of Texas at Austin · USUniversity of Michigan · USStony Brook University · USUniversity of Pennsylvania · US

Funding

Establishing Moderators/Biosignatures of Antidepressant Response- Clinical CareU01MH092221 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2010 to 2015
$9.7M
Biosignatures of Treatment Remission in Major DepressionU01MH092250 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MCGRATH, PATRICK J, PARSEY, RAMIN V. · 2010 to 2015
$8.9M
NIMH NIH HHS U01 MH092221NIMH NIH HHS U01 MH092250
6 · The paper itself

Abstract

Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.

Indexed as

RewardAdultAntidepressive AgentsFemaleHumansMajor Depressive DisorderMaleSertralineVentral StriatumAntidepressive AgentsSertraline

Identifiers

PMID31462766
PMCPMC7047617
OpenAlexW2971162380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.